New Treatment Options for Patients with Metastatic Prostate Cancer: What Is the Optimal Sequence?

Joyce M. Van Dodewaard-De Jong, Henk M W Verheul, Haiko J. Bloemendal, John M H De Klerk, Michael A Carducci, Alfons J M Van Den Eertwegh

Research output: Contribution to journalArticle

Abstract

Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patients develop castration-resistant prostate cancer, several new therapeutic strategies are available. Large trials have shown a survival benefit for patients treated with sipuleucel-T, docetaxel, cabazitaxel, abiraterone, enzalutamide, or radium-223. Along with these new available treatment options, the sequence of applying them has become a serious matter of debate. In this review we provide an overview of current systemic treatment options for metastatic prostate cancer and propose considerations to optimally sequence registered new therapies. In addition, we hypothesize on improvement of outcome with potential combination strategies.

Original languageEnglish (US)
Pages (from-to)271-279
Number of pages9
JournalClinical Genitourinary Cancer
Volume13
Issue number4
DOIs
StatePublished - Aug 1 2015

Fingerprint

Prostatic Neoplasms
docetaxel
Therapeutics
Radium
Survival
Castration
Androgens

Keywords

  • Chemotherapy
  • Hormonal therapy
  • Immunotherapy
  • Prostate cancer
  • Radiopharmaceuticals

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Van Dodewaard-De Jong, J. M., Verheul, H. M. W., Bloemendal, H. J., De Klerk, J. M. H., Carducci, M. A., & Van Den Eertwegh, A. J. M. (2015). New Treatment Options for Patients with Metastatic Prostate Cancer: What Is the Optimal Sequence? Clinical Genitourinary Cancer, 13(4), 271-279. https://doi.org/10.1016/j.clgc.2015.01.008

New Treatment Options for Patients with Metastatic Prostate Cancer : What Is the Optimal Sequence? / Van Dodewaard-De Jong, Joyce M.; Verheul, Henk M W; Bloemendal, Haiko J.; De Klerk, John M H; Carducci, Michael A; Van Den Eertwegh, Alfons J M.

In: Clinical Genitourinary Cancer, Vol. 13, No. 4, 01.08.2015, p. 271-279.

Research output: Contribution to journalArticle

Van Dodewaard-De Jong, JM, Verheul, HMW, Bloemendal, HJ, De Klerk, JMH, Carducci, MA & Van Den Eertwegh, AJM 2015, 'New Treatment Options for Patients with Metastatic Prostate Cancer: What Is the Optimal Sequence?', Clinical Genitourinary Cancer, vol. 13, no. 4, pp. 271-279. https://doi.org/10.1016/j.clgc.2015.01.008
Van Dodewaard-De Jong, Joyce M. ; Verheul, Henk M W ; Bloemendal, Haiko J. ; De Klerk, John M H ; Carducci, Michael A ; Van Den Eertwegh, Alfons J M. / New Treatment Options for Patients with Metastatic Prostate Cancer : What Is the Optimal Sequence?. In: Clinical Genitourinary Cancer. 2015 ; Vol. 13, No. 4. pp. 271-279.
@article{e52d7558ae064c35ac83aa569296c6fd,
title = "New Treatment Options for Patients with Metastatic Prostate Cancer: What Is the Optimal Sequence?",
abstract = "Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patients develop castration-resistant prostate cancer, several new therapeutic strategies are available. Large trials have shown a survival benefit for patients treated with sipuleucel-T, docetaxel, cabazitaxel, abiraterone, enzalutamide, or radium-223. Along with these new available treatment options, the sequence of applying them has become a serious matter of debate. In this review we provide an overview of current systemic treatment options for metastatic prostate cancer and propose considerations to optimally sequence registered new therapies. In addition, we hypothesize on improvement of outcome with potential combination strategies.",
keywords = "Chemotherapy, Hormonal therapy, Immunotherapy, Prostate cancer, Radiopharmaceuticals",
author = "{Van Dodewaard-De Jong}, {Joyce M.} and Verheul, {Henk M W} and Bloemendal, {Haiko J.} and {De Klerk}, {John M H} and Carducci, {Michael A} and {Van Den Eertwegh}, {Alfons J M}",
year = "2015",
month = "8",
day = "1",
doi = "10.1016/j.clgc.2015.01.008",
language = "English (US)",
volume = "13",
pages = "271--279",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - New Treatment Options for Patients with Metastatic Prostate Cancer

T2 - What Is the Optimal Sequence?

AU - Van Dodewaard-De Jong, Joyce M.

AU - Verheul, Henk M W

AU - Bloemendal, Haiko J.

AU - De Klerk, John M H

AU - Carducci, Michael A

AU - Van Den Eertwegh, Alfons J M

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patients develop castration-resistant prostate cancer, several new therapeutic strategies are available. Large trials have shown a survival benefit for patients treated with sipuleucel-T, docetaxel, cabazitaxel, abiraterone, enzalutamide, or radium-223. Along with these new available treatment options, the sequence of applying them has become a serious matter of debate. In this review we provide an overview of current systemic treatment options for metastatic prostate cancer and propose considerations to optimally sequence registered new therapies. In addition, we hypothesize on improvement of outcome with potential combination strategies.

AB - Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patients develop castration-resistant prostate cancer, several new therapeutic strategies are available. Large trials have shown a survival benefit for patients treated with sipuleucel-T, docetaxel, cabazitaxel, abiraterone, enzalutamide, or radium-223. Along with these new available treatment options, the sequence of applying them has become a serious matter of debate. In this review we provide an overview of current systemic treatment options for metastatic prostate cancer and propose considerations to optimally sequence registered new therapies. In addition, we hypothesize on improvement of outcome with potential combination strategies.

KW - Chemotherapy

KW - Hormonal therapy

KW - Immunotherapy

KW - Prostate cancer

KW - Radiopharmaceuticals

UR - http://www.scopus.com/inward/record.url?scp=84930828589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930828589&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2015.01.008

DO - 10.1016/j.clgc.2015.01.008

M3 - Article

C2 - 25704270

AN - SCOPUS:84930828589

VL - 13

SP - 271

EP - 279

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 4

ER -